Location History:
- Welwyn Garden, GB (2001 - 2005)
- Welwyn Garden City, GB (2003 - 2007)
Company Filing History:
Years Active: 2001-2007
Title: Michael Geoffrey Neil Russell: Innovator in GABA Receptor Ligands
Introduction
Michael Geoffrey Neil Russell is a notable inventor based in Welwyn Garden City, GB. With a strong portfolio of eight patents, he has made significant contributions to the field of medicinal chemistry, particularly focusing on GABA receptor ligands.
Latest Patents
Two of his latest patents involve a class of imidazo-triazine derivatives designed as selective ligands for GABA receptors. The first patent describes imidazo[1,2][1,2,4]triazine derivatives that are substituted at the 7-position by various five-membered or six-membered heteroaromatic rings. These compounds demonstrate good affinity for the α2, α3, and α5 subunits of GABA receptors, offering potential therapeutic benefits for central nervous system conditions such as anxiety, convulsions, and cognitive disorders.
The second patent focuses on 7-phenylimidazo[1,2-b][1,2,4]triazine derivatives. These derivatives are characterized by a substitution at the meta position of the phenyl ring, as well as further modifications that enhance their selectivity and affinity for the same GABA receptor subunits. This innovation also plays a crucial role in addressing various neurological issues.
Career Highlights
Throughout his career, Michael Russell has worked for prominent companies in the pharmaceutical industry, including Merck Sharp & Dohme Corporation and Merck Sharpe & Dohme Corp. His expertise and innovations have positioned him as a key contributor in the development of new therapeutic agents.
Collaborations
Michael has collaborated with respected professionals in the field, such as David James Hallett and Leslie Joseph Street. These partnerships underscore his commitment to advancing the field of pharmacology and enhancing clinical outcomes through innovative research.
Conclusion
Michael Geoffrey Neil Russell stands out as a leading inventor in the realm of GABA receptor ligands, contributing valuable insights and innovations through his patents and collaborative efforts. His ongoing work is expected to have a significant impact on the treatment of various central nervous system disorders.